Evaluation of the impact of the COVID-19 pandemic on treatment response of newly diagnosed people living with HIV: Turkey experience
Makaleler > Tam Makale · 2024
Yazarlar: Çiğdem ATAMAN HATİPOĞLU, Halis Akalın, Serhat Ünal, Meliha Çağla Sönmezer, Volkan Korten, Buket Ertürk Şengel, Yeşim Taşova, Ferit Kuşçu, Deniz Gökengin, Nazlıhan Yalçın Ege, Selda Sayın Kutlu, Firuze Soyak, Figen Kaptan Aydoğmuş, Beyza Erol, Şua Sümer, Nazlım Aktuğ Demir, Gönül Çiçek Şentürk, Semanur Kuzi, Uğur Emre Gümüş, Esra Kaya Kılıç, Günay Tuncer Ertem, Sami Kınıklı, Sabri Atalay, Gürsel Ersan, Adalet Altunsoy, Halime Araz, Taner Yıldırmak, Rıdvan Dumlu, İlkay Karaoğlan, Ayşe Özlem Mete, Asuman İnan, Serhat Birengel, Ezgi Gülten, Zehra Karacaer, Dilara İnan, Samet Acar, Emel Yilmaz, Pınar Ergen, Özlem Aydin, Şerife Barçın Öztürk, Petek Şarlak Konya, Aysel Kocagül Çelikbaş, Yüksel Karadağ, Mustafa Kemal Çelen, Çiğdem Mermutluoğlu
Journal of Global Antimicrobial Resistance, Uluslararası, Wos, 2024, cilt 39, ss 51-52
DOI: 10.1016/j.jgar.2024.10.165
Özet
To evaluate the antiretroviral treatment (ART) in newly diagnosed people living with HIV (PLWH) and to determine treatment response in pre-pandemic and pandemic periods. The COVID-19 pandemic has negatively affected the treatment processes of PLWH. This multi-centred, retrospective study included newly diagnosed PLWH aged ≥18 years, between pre-pandemic (01.03.2018-29.02.2020) and pandemic (01.03.2020-28.02.2022) period. Demographic data and ART were recorded. Of 2400 PLWH from 23 centres, 88% were male; mean age was 37,5±12,5. At diagnosis, mean CD4 count was 398/mm3, CD4/CD8 ratio 0,47, HIV-RNA 12288990 copies/ml. Among patients, 52% diagnosed during pre-pandemic, 48% during pandemic period. Thirty patients could not be treated because one died before treatment, 29 did not re-apply after diagnosis. Of remaining 2370 patients, 93,4% were started on ≥3 antiretroviral drugs, 6,6% on dual therapy; 97,8% were integrase inhibitor (INSTI), 1,8% protease inhibitor (PI), 0,4% non-nucleoside reverse transcriptase inhibitor (NNRTI) based. Of patients, 64,5% were receiving single-tablet, 35,5% multiple-tablet regimen. The mean CD4 count at 6th month was 602/mm3, CD4/CD8 ratio 0,72. HIV-RNA negativity rates at 1st, 3rd, 6th months were 49%, 76%, 88%, respectively. Comparison of two periods is shown in Table 1. INSTI based combinations (p=0,002) and dual therapy (p=0,000) were used more frequently during the pandemic period. Mean CD4 count, CD4/CD8 ratio at 6th month, and HIV RNA negativity rates were similar in both periods (p>0,05). INSTI based combinations and two-tablet regimens were used more frequently during the pandemic period. The treatment response was similar in both periods.